Abivax S.A.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Accelerated filerEmerging growth company
State of Incorporation
France
Country
France
Business Address
7 BD HAUSSMANN, PARIS, ,
Mailing Address
7 BD HAUSSMANN, PARIS, ,
Phone
01 53 83 09 63
Fiscal Year End
1231
EIN
000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 20-F Foreign company annual report | March 23, 2026 | View on SEC |
| 6-K Foreign company current report | March 23, 2026 | View on SEC |
| 6-K Foreign company current report | February 23, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | January 14, 2026 | View on SEC |
| 6-K Foreign company current report | December 15, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | October 30, 2025 | View on SEC |
| 6-K Foreign company current report | September 8, 2025 | View on SEC |
Annual Reports
20-F
March 23, 2026
- Obefazimod's Phase 3 program for Ulcerative Colitis (UC) is on track, with patient enrollment progressing for the ABTECT study.
- Successfully raised over $350 million in 2023 through various funding rounds and share sales, extending cash runway into the second half of 2025.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.